Soleno Withdraws EU Drug Application for Vykat XR Ahead of Neurocrine Acquisition
SLNO sits 78% above its 52-week low of $29.43 on elevated volume (4.0× avg).
Summary
Soleno Therapeutics has voluntarily withdrawn its European marketing application for Vykat XR, its rare metabolic disorder drug for Prader-Willi syndrome. This strategic decision follows the recently announced acquisition by Neurocrine Biosciences, which intends to focus on the U.S. market for the drug. The withdrawal removes a significant potential future revenue stream from the European market for Vykat XR, clarifying Neurocrine's post-acquisition strategy for this key asset. While the acquisition itself was the primary market mover, this news provides important details on the future commercialization path of Vykat XR. Investors will now focus on the successful completion of the Neurocrine acquisition and its U.S. market execution for Vykat XR.
At the time of this announcement, SLNO was trading at $52.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $29.43 to $90.32. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.